Logo for MindBio Therapeutics Corp.
MBIO
0.00%

MindBio Therapeutics Corp.

Statut
ActifT2
Émis et en Circulation142,957,291
Réservé pour Émission35,290,988
DeviseCAD
CSE IndiceNo

Citation

Dernier Prix0.00 (0.00%)
Volume0
Changement0.00
Taille de l'offre0
Prix de l'offre
Prix de la demande
Taille de la demande0
Clôture précédente
Ouverture
Haut du jour
Bas du jour
Haut de 52 semaines
Bas de 52 semaines

MindBio Therapeutics Corp.

Graphiques par TradingView

Affichage de la profondeur

Transactions Récentes

À propos

MindBio Therapeutics Corp.

Date d'inscription
05 mai 2023

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials.  MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing.  MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. The Company has also started dosing in a Phase 2B Depression Trial.   MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.